Ablynx and Merck Serono have expanded their partnership through a multi-year research alliance that could lead to four discovery and development collaborations. Merck Serono will fund a dedicated discovery group at Ablynx and both partners will select disease targets and develop nanobodies through in vivo proof-of-principle. The group will focus on nanobodies against a number of targets across multiple disease areas, including oncology, immuno-oncology, immunology and neurology.   The alliance w...